Read by QxMD icon Read


Uri Landes, Danny Dvir, Wolfgang Schoels, Christopher Tron, Stephan Ensminger, Matheus Simonato, Ulrich Schäfer, Matjaz Bunc, Gabriel Aldea, Alfredo Cerillo, Stephan Windecker, Antonio Marzocchi, Martin Andreas, Nicolas Amabile, John Webb, Ran Kornowski
AIMS: To evaluate transcatheter aortic valve-in-valve implantation performance in rapid deployment (ViVr) vs. conventional (ViVc) surgical heart valve (SHV). METHODS AND RESULTS: A multicenter registry was developed as part of the VIVID international registry. A total of 30 ViVr [Perceval (Sorin Biomedica, Salugia, Italy), n=24, the ATS 3F Enable (Medtronic Inc., Minneapolis, MN, USA), n=5, and the Intuity (Edwards Lifesciences, Irvine, CA, USA), n=1] were evaluated and compared with 2,288 ViVc patients...
February 19, 2019: EuroIntervention
Isaac Pascual, Pablo Avanzas, Daniel Hernández-Vaquero, Rocío Díaz, Raquel Del Valle, Remigio Padrón, Rebeca Lorca, Victor León, María Martín, Fernando Alfonso, César Morís
BACKGROUND: The aim of this study was to assess the safety and effectiveness of valve in valve (VIV) TAVI with the autoexpandable valve, specifically in patients with failed Mitroflow (MF) bioprosthetic aortic valves. METHODS: Pilot, single center, observational and prospective study that included 45 consecutive patients with symptomatic failed MF bioprosthetic aortic valve, referred for VIV TAVI. The safety primary endpoint was a composite of early events at 30 days, defined by VARC-2 criteria...
February 1, 2019: International Journal of Cardiology
François Huchet, Jacques Chan-Peng, Fanny d'Acremont, Patrice Guerin, Gael Grimandi, Jean-Christian Roussel, Julien Plessis, Vincent Letocart, Thomas Senage, Thibaut Manigold
BACKGROUND: Current scientific guidelines have extended the indication for transcatheter aortic valve replacement (TAVR) to patients who present an intermediate risk for surgery and have been so far considered for conventional surgery. We previously demonstrated that the TAVR procedure generated profits despite elevated costs, but comparison with surgery has not been performed. The objective of this study was to assess the profitability of the TAVR procedure compared with conventional surgery in a high-volume French hospital...
February 14, 2019: Health Economics Review
Dariusz Jagielak, Aleksandra Stanska, Andrzej Klapkowski, Maciej Brzezinski, Maciej Kowalik, Dariusz Ciecwierz, Milosz Jaguszewski, Marcin Fijalkowski
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become a standard therapeutic option for patients with severe aortic stenosis (AS) at high cardiac surgical risk. The aim of the NAUTILUS study was to investigate the safety and performance of the New Valve Technology (NVT) Allegra bioprosthesis in high-risk patients undergoing TAVI. METHODS: 27 patients with severe, symptomatic AS at high surgical risk were prospectively enrolled, who underwent treatment using the novel self-expanding NVT Allegra bioprosthesis via transfemoral approach (TF-TAVI)...
February 14, 2019: Cardiology Journal
Benyamin Rahmani, Christopher McGregor, Guerard Byrne, Gaetano Burriesci
Bioprosthetic leaflets made from animal tissues are used in the majority of surgical and transcatheter cardiac valve replacements. This study develops a new surgical bioprosthesis, using porcine pericardial leaflets. Porcine pericardium was obtained from genetically engineered pigs with a mutation in the GGTA-1 gene (GTKO) and fixed in 0.6% glutaraldehyde, and used to develop a new surgical valve design. The valves underwent in vitro hydrodynamic test in a pulse duplicator and high-cycled accelerated wear testing and were evaluated for acute haemodynamics and thrombogenicity in a juvenile sheep implant study for 48 h...
February 12, 2019: Journal of Cardiovascular Translational Research
Andreas Eicken, Peter Ewert
Severe tricuspid valve (TV) dysfunction in patients with congenital heart disease (CHD) is usually treated by open heart surgery in relatively young patients. If a valve plasty is not possible, a biological valve is implanted with a limited durability. Due to valve degeneration repeated valve exchanges are necessary in these patients. To expand the lifetime of a bioprosthesis in tricuspid position percutaneous TV implantation (PTVI) was introduced recently. PTVI is a promising new catheter interventional technology...
December 2018: Cardiovascular Diagnosis and Therapy
Bo Yang, Elizabeth L Norton, Reilly Hobbs, Linda Farhat, Xiaoting Wu, Whitney E Hornsby, Karen M Kim, Himanshu J Patel, G Michael Deeb
OBJECTIVE: The study objective was to evaluate the perioperative and long-term outcomes of aortic root repair and aortic root replacement and provide evidence for root management in acute type A aortic dissection. METHODS: From 1996 to 2017, 491 patients underwent aortic root repair (n = 307) or aortic root replacement (n = 184) (62% bioprosthesis) for acute type A aortic dissection. Indications for aortic root replacement were intimal tear at the aortic root, root measuring 4...
December 21, 2018: Journal of Thoracic and Cardiovascular Surgery
Patrizio Lancellotti, Christophe Martinez, Marc Radermecker
No abstract text is available yet for this article.
February 12, 2019: Journal of the American College of Cardiology
Vi Vu, Lorenzo Rossini, Ricardo Montes, Josue Campos, Juyeun Moon, Pablo Martinez-Legazpi, Javier Bermejo, Juan C Del Álamo, Karen May-Newman
Dilated cardiomyopathy produces abnormal left ventricular (LV) blood flow patterns that are linked with thromboembolism (TE). We hypothesized that implantation of mechanical heart valves non-trivially influences TE risk in these patients, exacerbating abnormal LV flow dynamics. The goal of this study was to assess how mitral valve design impacts flow and hemodynamic factors associated with TE. The mid-plane velocity field of a silicone dilated LV model was measured in a mock cardiovascular loop for three different mitral prostheses, two with multiple orientations, and used to characterize LV vortex properties through the cardiac cycle...
February 6, 2019: Annals of Biomedical Engineering
Guilherme Viotto, Leonardo Paim, Renato Souza, Joaquim Aprígio, Lucas Lacerda, Pablo Pomerantzeff, Marcelo B Jatene, José Honório Palma, Fabio B Jatene
OBJECTIVES: In this study, we sought to evaluate early outcomes of transcatheter valve-in-valve implantation in patients with a degenerated bioprosthesis in the tricuspid position. METHODS: We used a prospective study, which included patients with a degenerated bioprosthesis in the tricuspid position who were considered high-risk by our heart team and who underwent a valve-in-valve implantation. The procedures were performed via transjugular venous access and were done with the patient under general anaesthesia with transoesophageal echocardiographic and fluoroscopic guidance...
January 25, 2019: Interactive Cardiovascular and Thoracic Surgery
Enrico Ferrari, Stefan Stortecky, Dik Heg, Olivier Muller, Fabian Nietlispach, David Tueller, Stefan Toggweiler, Stéphane Noble, Francesco Maisano, Marco Roffi, Raban Jeger, Jürg Grünenfelder, Christoph Huber, Stephan Windecker, Peter Wenaweser
OBJECTIVES: The SwissTAVI Registry includes all consecutive patients undergoing transcatheter aortic valve implantation (TAVI) and valve-in-valve (VinV) procedures for a failed bioprosthesis in Switzerland. We report the real world, all-comers, 30-day and 1-year outcomes of patients undergoing VinV and standard TAVI procedures. METHODS: Prospectively collected data from the 2 groups (VinV and standard TAVI patients) were retrospectively analysed. In an adjusted analysis, in-hospital and 1-year outcomes of VinV patients were compared with those of patients undergoing TAVI for native aortic valve disease in the same registry...
January 27, 2019: European Journal of Cardio-thoracic Surgery
Ferdinand Vogt, Marco Moscarelli, Anna Nicoletti, Renato Gregorini, Francesco Pollari, Jurji M Kalisnik, Steffen Pfeiffer, Theodor Fischlein, Giuseppe Santarpino
BACKGROUND: Several studies reported high rates of postoperative permanent pacemaker (PPM) implantation, which has been described as the "Achilles' heel" of sutureless aortic valve replacement (AVR). METHODS: From July 2010 to December 2017, 3158 patients with symptomatic, severe aortic valve stenosis were referred to our cardiac surgery center and 512 received a Perceval sutureless bioprosthesis. Thirty-nine patients who had been discharged with concomitant PPM implantation were re-evaluated...
January 23, 2019: Annals of Thoracic Surgery
Markus Kofler, Axel Unbehaun, Christoph Klein, Alexander Meyer, Semih Buz, Matthias Hommel, Volkmar Falk, Jörg Kempfert
Transcatheter aortic valve implantation has dramatically changed the treatment of valvular heart disease over the past decade. At the same time, the indications for bioprosthesis implantation have been continuously extended toward younger patients, driven by excellent clinical results and improved durability. While the omission of oral anticoagulation reduces the risk of severe bleeding complications, the long-term durability of bioprostheses is still limited. In light of the growing number of elderly transcatheter aortic valve replacement (TAVR) patients, the prevalence of patients with failed bioprostheses and advanced comorbidities is expected to rise...
January 18, 2019: Surgical Technology International
Yuki Ikeno, Nobuhiko Mukohara, Yoshiaki Fukumura, Satoshi Tobe, Kunio Gan, Hidefumi Obo, Kazunori Yoshida, Yutaka Okita
OBJECTIVE: To evaluate the long-term outcomes of heart valve replacement with mechanical prosthesis (MP) versus bioprosthesis (BP) in patients on dialysis. METHODS: A retrospective review was performed at 7 hospitals. Patients on dialysis who underwent valve replacement were included. Survival, reoperation, bleeding, and embolic events were compared across the MP and BP groups. RESULTS: Between April 2000 and April 2016, 312 patients on dialysis were enrolled in our study (MP: 94 patients [30...
December 4, 2018: Journal of Thoracic and Cardiovascular Surgery
Grzegorz Filip, Radoslaw Litwinowicz, Boguslaw Kapelak, Jacek Piatek, Magdalena Bartus, Janusz Konstanty-Kalandyk, Maciej Brzezinski, Krzysztof Bartus
Background: Aortic stenosis (AS) is the most common valve disease in the adult population and its prevalence increases with age. Unfortunately, older age and comorbidities significantly increase mortality, operative risk and worsen prognosis. In recent years, sutureless bioprosthesis [sutureless-aortic valve replacement (SU-AVR)] has become an alternative to standard AVR or TAVI in high-risk patients. Compared to standard AVR, the advantages of SU-AVR include shorter valve implantation, shorter aortic cross clamp (ACC) and cardiopulmonary bypass (CPB) times and higher valve EOA with more favorable hemodynamic parameters...
November 2018: Journal of Thoracic Disease
Emiliano A Rodríguez-Caulo, Diego Macías, Alejandro Adsuar, Andrea Ferreiro, Javier Arias-Dachary, Gertrudis Parody, Frank Fernández, Tomás Daroca, Felipe Rodríguez-Mora, José M Garrido, Ignacio Muñoz-Carvajal, José M Barquero, José F Valderrama, José M Melero
OBJECTIVES: The decision about whether to use a biological or a mechanical prosthesis for aortic valve replacement remains controversial in patients between 50 and 65 years of age and has yet to be addressed in a Mediterranean population. This research aimed to analyse long-term survival and major morbidity rates (30-day mortality, stroke, any prosthetic reoperation and major bleeding) within this population. METHODS: Our multicentre observational retrospective study included all subjects aged 50-65 years who had a primary isolated aortic valve replacement due to severe aortic stenosis at 7 public hospitals from Andalusia (Spain) between 2000 and 2015...
January 3, 2019: European Journal of Cardio-thoracic Surgery
Jordan P Bloom, Michael H Kwon, George Tolis
Early distal migration after transcatheter aortic valve replacement (TAVR) is a rare but potentially catastrophic complication that presents unique technical challenges for subsequent surgical management. We report a case of early distal migration of a Medtronic CoreValve Evolut R bioprosthesis causing myocardial infarction from coronary ostial obstruction and a practical technique for open surgical device explantation and aortic valve re-replacement. Snaring the stent of the device using standard instruments is a simple but effective method for TAVR explant that allows for optimal positioning of a single aortotomy at the standard anatomic site to facilitate subsequent surgical AVR...
December 26, 2018: Annals of Thoracic Surgery
Maarten P van Wiechen, Nicolas M Van Mieghem
The only curative treatment of aortic stenosis is through surgical or transcatheter aortic valve replacement. Transcatheter aortic valve implantation has evolved from its first in human experience in 2002 and matured to the treatment of first choice of symptomatic severe aortic stenosis in elderly patients with an elevated operative risk. The self-expanding CoreValve® bioprosthesis has been on the forefront of this growing transcatheter aortic valve implantation experience. Over the last decade, various device iterations resulted in the current Evolut PRO® self-expanding valve platform with reduced profile, repositioning/retrievable features and porcine pericardial wrap...
December 19, 2018: Future Cardiology
Roberta Antonazzo Panico, Cristina Giannini, Marco De Carlo, Marco Angelillis, Paolo Spontoni, Andrea Pieroni, Giulia Costa, Pietro Bertini, Fabio Guarracino, Anna Sonia Petronio
AIMS: to determine long-term outcomes of high-risk patients who underwent transcatheter aortic valve implantation (TAVI) with third-generation CoreValve device, according to the 2017 EAPCI/ESC/EACTS definition of valve durability. METHODS AND RESULTS: between 2007 and 2013, 278 consecutive patients were enrolled in our prospective single-centre CoreValve registry (mean age 82±6 years, mean STS score 6.4±5.0%); median follow-up of survivors was 6.8 years. The Cox proportional hazards model was used to identify independent predictors of HF-rehospitalization and all-cause mortality...
December 18, 2018: EuroIntervention
P V Lednev, A V Stonogin, A V Lysenko, T G Nikityuk, G I Salagaev, Yu V Belov
Case report of successful conservative treatment of patient with thrombosis of aortic valve bioprosthesis after 8 months postoperatively is presented.
2018: Khirurgiia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"